Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ABBV-31 · ABBV-319

Antibody-drug conjugate · Immune activation, directed at CD19 · developed by AbbVie

Phase 1 Most advanced trial
ABBV Developer
1 Registered trials

What is ABBV-31?

ABBV-31 (ABBV-319) is an antibody drug conjugate of an afucosylated IgG1 antibody binding the B-cell surface protein CD19, linked to a glucocorticoid receptor modulator payload. The antibody engages antibody-dependent cellular cytotoxicity, and the payload delivered into CD19-expressing cells inhibits glucocorticoid receptor-driven expression of proliferative and anti-apoptotic genes. It is being studied in systemic lupus erythematosus and dry eye syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ABBV-319
Drug type
Antibody-drug conjugate
Targets
CD19, glucocorticoid receptor (NR3C1) (secondary target)
Mechanism
Immune activation, directed at CD19
Pathways
antibody-dependent cellular cytotoxicity, glucocorticoid receptor-dependent gene expression, apoptosis
Therapy area
Immunology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06977724 Phase 1 Dry Eye Syndrome Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye SyndromeSystemic Lupus Erythematosus

Other drugs acting on CD19

More from AbbVie

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind ABBV-31

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.